- Report
- August 2024
- 80 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- October 2023
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 172 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2025
- 85 Pages
India
From €3340EUR$3,500USD£2,799GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- September 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- July 2022
- 186 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- February 2024
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2023
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2023
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- April 2023
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- January 2024
- 140 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 125 Pages
Africa, Middle East
From €3293EUR$3,450USD£2,759GBP
- Report
- November 2023
- 120 Pages
From €3293EUR$3,450USD£2,759GBP
- Report
- February 2023
- 206 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- March 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more